During the past decade, Tampa General Medical Group conducted 20 clinical trials. In the 10-year time frame, 20 clinical trials started and 21 clinical trials were completed, i.e. on average, 105% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 18 clinical trials were completed. i.e. 257.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tampa General Medical Group" #1 sponsor was "Pfizer" with 8 trials, followed by "Human Genome Sciences Inc." with 5 trials sponsored, "Eli Lilly and Company" with 4 trials sponsored, "Amgen" with 3 trials sponsored and "AstraZeneca" with 3 trials sponsored. Other sponsors include 25 different institutions and companies that sponsored additional 31 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tampa General Medical Group" #1 collaborator was "Incyte Corporation" with 3 trials as a collaborator, "GlaxoSmithKline" with 2 trials as a collaborator, "Dr. Naga Chalasani, MD, Indiana University" with 1 trials as a collaborator, "Dr. Stephen A. Harrison, MD, Brooke Army Medical Center" with 1 trials as a collaborator and "ICON Clinical Research" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Tampa General Medical Group" are "Rheumatoid Arthritis" (9 trials), "Systemic Lupus Erythematosus" (6 trials), "Osteoarthritis" (5 trials), "Nonalcoholic Steatohepatitis" (3 trials) and "Acute Gout" (2 trials). Many other conditions were trialed in "Tampa General Medical Group" in a lesser frequency.

Most popular intervention types in "Tampa General Medical Group" are "Drug" (47 trials), "Biological" (6 trials) and "Other" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (22 trials), "Baricitinib" (4 trials), "AC2993" (3 trials), "Belimumab 1 mg/kg" (3 trials) and "Belimumab 10 mg/kg" (3 trials). Other intervention names were less common.

The vast majority of trials in "Tampa General Medical Group" are 51 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Tampa General Medical Group". undefined are not yet recruiting, 6 are recruiting, 1 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 32 completed trials in Tampa General Medical Group, undefined suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in Tampa General Medical Group, 0 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 26 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 0 trials that are defined as “Not Applicable".